The Journal of Nuclear Medicine最新文献

{"title":"Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein–Targeted Imaging—FAP-RADS Version 1.0","authors":"Emil Novruzov, Gabriel T. Sheikh, Eduards Mamlins, Adrien Holzgreve, Yuriko Mori, Stephan Ledderose, Frederik Klauschen, Tadashi Watabe, Michael A. Gorin, Martin G. Pomper, Ken Herrmann, Steven P. Rowe, Rudolf A. Werner, Frederik L. Giesel","doi":"10.2967/jnumed.125.269914","DOIUrl":"https://doi.org/10.2967/jnumed.125.269914","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.269914absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"402 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study","authors":"Stefano Fanti, Javier Jesus Robles Barba, Spencer Behr, Tobias Maurer, Pilar Paredes, Jochen Walz, Joan Duch, Marc Simo Perdigo, Ismini Charis Mainta, Pierre Benoit Bonnefoy, Medge Coulanges, Jun Tang, Christelle Seigne, Celine Wilke, Ana M. Catafau, Andrei Iagaru, Rahul Aggarwal","doi":"10.2967/jnumed.124.269266","DOIUrl":"https://doi.org/10.2967/jnumed.124.269266","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269266absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine–Refractory Metastatic Thyroid Cancer","authors":"Johannes von Hinten, Oliver Viering, Ralph A. Bundschuh, Feyza Cagliyan, Hermann Wengenmair, Christian H. Pfob, James Nagarajah, Constantin Lapa, Malte Kircher","doi":"10.2967/jnumed.125.270055","DOIUrl":"https://doi.org/10.2967/jnumed.125.270055","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.270055absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer","authors":"Sara S. Rinne, Daniela Burnes Vargas, Shin Seo, Darren Veach, Michael R. McDevitt, Brett A. Vaughn, Hong Xu, Hong-Fen Guo, Edward K. Fung, Elisa de Stanchina, Ileana C. Miranda, Steven M. Larson, Nai Kong V. Cheung, Sarah M. Cheal","doi":"10.2967/jnumed.125.269601","DOIUrl":"https://doi.org/10.2967/jnumed.125.269601","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.269601absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177Lu in Preclinical Models of Ovarian Cancer","authors":"Tihomir Zh. Todorov, Ricardo Coelho, Sharon Dellea, Francis Jacob, Viola Heinzelmann-Schwarz, Pascal V. Grundler, Nicholas P. van der Meulen, Martin P. Béhé, Roger Schibli, Jürgen Grünberg","doi":"10.2967/jnumed.124.269078","DOIUrl":"https://doi.org/10.2967/jnumed.124.269078","url":null,"abstract":"&lt;p&gt;Cancer stem cells (CSCs) are highly tumorigenic, self-renewable cells with a key role in tumor relapse, metastasis, and therapy resistance. Effective CSC-targeted therapies remain an unmet clinical need, strongly dependent on the selection of suitable targets and thorough validation of therapeutic agents. L1 cell adhesion molecule (L1CAM) is a targetable CSC-associated biomarker aberrantly expressed in various malignancies, including ovarian cancer (OC). &lt;sup&gt;161&lt;/sup&gt;Tb is attractive for clinical application because of its substantial emission of conversion electrons/Auger electrons as well as β&lt;sup&gt;–&lt;/sup&gt; emission. Leveraging the high cytotoxicity of conversion electrons/Auger electrons, &lt;sup&gt;161&lt;/sup&gt;Tb is promising for radioimmunotherapy against radioresistant tumor cells such as CSCs. The aim of this study was to confirm the presence of L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; ovarian CSCs in patient samples and preclinically investigate, in a tumor prevention mouse model, &lt;sup&gt;161&lt;/sup&gt;Tb-based anti-L1CAM radioimmunotherapy as a new therapeutic modality against CSCs compared with &lt;sup&gt;177&lt;/sup&gt;Lu-based anti-L1CAM radioimmunotherapy. &lt;strong&gt;Methods&lt;/strong&gt;: L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs were examined in OC samples by immunofluorescence. After radiolabeling anti-L1CAM DOTA-chCE7 with &lt;sup&gt;177&lt;/sup&gt;Lu or &lt;sup&gt;161&lt;/sup&gt;Tb and purification, we assessed radioimmunoconjugate quality by determining the radiochemical purity and the immunoreactive fraction. The internalized and membrane-bound fractions and the radiocytotoxicity of radiolabeled DOTA-chCE7 were evaluated with cell uptake and cell proliferation assays. Ovarian L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs were sorted via fluorescence-activated cell sorting from OVCAR8 and SKOV3ip cells and inoculated into immunocompromised mice, who then received treatment with [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTA-chCE7 or [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-chCE7. &lt;strong&gt;Results&lt;/strong&gt;: L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs (0.3%–21%) were confirmed in samples from patients who were chemotherapy-naïve or had relapsed OC. [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTA-chCE7 and [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-chCE7 were produced with high radiochemical purity and retained 76%–96% immunoreactivity. Cell uptake after 15 h ranged from 50% to 75% for both radioimmunoconjugates. [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-chCE7 showed significantly increased cytotoxicity, eliminating all ovarian CSCs and tumor cells differentiated from the CSCs in vivo, compared with [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTA-chCE7 (3 tumors in OVCAR8 group and 1 tumor in SKOV3ip group). Follow-up tumor analysis confirmed that sorted ovarian L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs regenerated the tumor heterogeneity in vivo. &lt;strong&gt;Conclusion&lt;/strong&gt;: This work addresses the critical need for CSC-specific therapies in the clinics by establishing &lt;sup&gt;161&lt;/sup&gt;Tb-based anti-L1CAM radioimmunotherapy as a novel therapeutic modality against CSCs. We found that &lt;sup&gt;161&lt;/sup&gt;Tb-based anti-L1CAM ","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients","authors":"Stefan Schmitl, Elisabeth Kretschmer-Chott, Eva-Maria Patronas, Gero Kramer, Philipp Ritt, Elisabeth Fuchs, Maximilian Weisbrod, Lukas Nics, Markus Mitterhauser, Marcus Hacker","doi":"10.2967/jnumed.125.269655","DOIUrl":"https://doi.org/10.2967/jnumed.125.269655","url":null,"abstract":"<p>²²⁵Ac-labeled (<em>S</em>)-ibuprofen-diaminobutyric acid-PSMA (SibuDAB) is a novel, albumin-binding compound in prostate-specific membrane antigen (PSMA)–targeted α-therapy of prostate cancer. It showed superior preclinical efficacy results to [²²⁵Ac]Ac-PSMA-617. ²²⁵Ac decays via multiple α-particle emissions. The full therapeutic potential requires fast tumor uptake and retention of parent and daughter nuclides, such as ²¹³Bi, in the tumor. High decay energies lead to daughter nuclide recoil of the chelator and, therefore, altered pharmacokinetics and potential irradiation of off-target organs. We hereby present clinical efficacy and safety data for [²²⁵Ac]Ac-SibuDAB, as well as blood kinetics and the ²¹³Bi distribution between blood and urine samples. <strong>Methods:</strong> Fifteen prostate cancer patients who received [²²⁵Ac]Ac-SibuDAB between December 2021 and August 2024 were included in this retrospective study. Patients were scheduled to receive 6 MBq of [²²⁵Ac]Ac-SibuDAB every 8 wk. The prostate-specific antigen (PSA) response was evaluated, and adverse events were categorized according to Common Terminology Criteria for Adverse Events, version 5.0. Blood pharmacokinetics were determined after blood sampling at different time points and measured in ²²⁵Ac/²²¹Fr equilibrium. The ²¹³Bi distribution was determined in blood and urine samples before reaching ²²⁵Ac/²¹³Bi equilibrium. <strong>Results:</strong> Fifteen patients received a total of 25 cycles with a median exposure of 6.55 MBq (range, 4.65–30.60 MBq). The Gleason score was available for 12 of the 15 patients, with 10 patients having a Gleason score of 8 or higher. The patients were heavily pretreated, including 13 patients with prior [¹⁷⁷Lu]Lu-PSMA therapy. Nine of the 15 patients showed any PSA decline, and 5 of the 15 patients showed a PSA decline of 50% or more. All patients showed grade 1 xerostomia. Treatment was stopped because of grade 3 thrombocytopenia in 1 of the 15 patients. [²²⁵Ac]Ac-SibuDAB blood kinetics were evaluated in 6 patients. ²¹³Bi blood and urine distribution studies were conducted on 3 patients and showed a vast net ²¹³Bi excess in urine immediately after application, a moderate excess at later time points, and a lack of ²¹³Bi in blood at any time point. <strong>Conclusion:</strong> [²²⁵Ac]Ac-SibuDAB initial clinical data show efficacy in heavily pretreated prostate cancer patients, with 1 patient experiencing treatment-limiting toxicity. Only limited signs of xerostomia were observed after the treatment. ²¹³Bi generated by recoil is rapidly distributed into urine after application of [²²⁵Ac]Ac-SibuDAB.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"248 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas","authors":"Elisa Rioja-Blanco, Yara Banz, Christoph Schlapbach, Urban Novak, Tanja Chiorazzo, Nicole L. Bertschi, Peter Bernhardt, Pascal V. Grundler, Nicholas P. van der Meulen, Michal Grzmil, Roger Schibli, Martin Behe","doi":"10.2967/jnumed.124.268805","DOIUrl":"https://doi.org/10.2967/jnumed.124.268805","url":null,"abstract":"<p>Lymphoma remains a significant health concern, necessitating innovative treatment approaches. ¹⁶¹Tb&rsquo;s coemission of ultra-short-range conversion and Auger electrons, with its medium-energy &beta;^&ndash;-particles, may enable the elimination of single cells and small clusters present in circulation, improving therapeutic outcomes. In this study, we compared ¹⁶¹Tb radioimmunotherapy targeting CD30&mdash;a receptor overexpressed in lymphomas&mdash;with ¹⁷⁷Lu-radiolabeled therapy to evaluate the effect of ¹⁶¹Tb&rsquo;s additional emission of conversion and Auger electrons. <b>Methods:</b> The ability of ¹⁶¹Tb- and ¹⁷⁷Lu-radiolabeled anti-CD30 antibody (cAC10) to reduce cell viability and survival and induce DNA damage was evaluated in&nbsp;vitro in CD30-positive T-cell lymphoma cell lines. The biodistribution, dosimetry, and therapeutic effect of both radioimmunoconjugates were studied in a xenograft mouse model. Xenografts treated with [¹⁶¹Tb]Tb-cAC10 and [¹⁷⁷Lu]Lu-cAC10 were submitted for quantitative proteomics and phosphoproteomics analyses, followed by bioinformatics analysis. <b>Results:</b> [¹⁶¹Tb]Tb-cAC10 demonstrated superior and CD30-specific cytotoxicity across a panel of T-cell lymphoma cell lines. In vivo studies showed a favorable biodistribution, with high tumor uptake (31.0 &plusmn; 7.4 percentage of injected activity per mass of tissue after 48 h) and a higher tumor-absorbed dose for ¹⁶¹Tb. Importantly, a single administration of the ¹⁶¹Tb-radiolabeled compound significantly prolonged survival time compared with an equal injected activity of [¹⁷⁷Lu]Lu-cAC10 (median survival, 41 d vs. 21 d). Phosphoproteomic analysis revealed that both [¹⁷⁷Lu]Lu-cAC10 and [¹⁶¹Tb]Tb-cAC10 induced alterations in pathways regulating DNA damage response and cell cycle, among others, with ¹⁶¹Tb inducing more pronounced changes than did ¹⁷⁷Lu. <b>Conclusion:</b> ¹⁶¹Tb radioimmunotherapy was an effective therapy for CD30-positive T-cell lymphomas. To our knowledge, this is the first evaluation of this therapeutic radionuclide for the treatment of hematologic malignancies. Additionally, in&nbsp;vivo phosphoproteomics provided insights into the biologic processes and pathways regulated by radioimmunotherapy administration, further supporting the superior efficacy of ¹⁶¹Tb over ¹⁷⁷Lu.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144193143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View","authors":"Xavier Palard-Novello, Denise Visser, Maqsood Yaqub, Elsmarieke van de Giessen, Marijke E. den Hollander, Albert D. Windhorst, Sander C.J. Verfaillie, Hans Knoop, Bart N.M. van Berckel, Sandeep S.V. Golla, Nelleke Tolboom, Ronald Boellaard","doi":"10.2967/jnumed.124.268979","DOIUrl":"https://doi.org/10.2967/jnumed.124.268979","url":null,"abstract":"<p>Multisystemic inflammation might be a key pathophysiologic mechanism in post–coronavirus disease 2019 (post-COVID) syndrome. <em>N,N-</em>diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)5,7dimethylpyrazolo[1,5a] pyrimidin-3-yl)acetamide ([¹⁸F]DPA-714), which binds with high affinity the translocator protein (TSPO) receptor, is used as a marker of inflammation. Therefore, quantifying [¹⁸F]DPA-714 uptake throughout the body could assess extracerebral inflammation in post-COVID syndrome. However, the pharmacokinetics of whole-body [¹⁸F]DPA-714 uptake have not yet been assessed. Thus, before quantifying whole-body [¹⁸F]DPA-714 uptake in post-COVID syndrome, the aim of this study was to identify the optimal pharmacokinetic model in different extracerebral organs. <strong>Methods:</strong> Thirty-nine post-COVID participants with high-affinity binding for TSPO with or without persistent complaints were enrolled from the prospective VeCosCO study. Whole-body dynamic [¹⁸F]DPA-714 PET/CT scans (0–60 min after injection) were performed. Ascending aorta–based image-derived input functions were corrected with manual arterial blood samples to establish metabolite-corrected plasma input functions. Time–activity curves were derived from volumes of interest in the adrenal gland, bone, kidney, liver, lung, myocardium, pancreas, skeletal muscle, spleen, and thyroid. [¹⁸F]DPA-714 kinetics were studied by nonlinear regression fitting of 1- and 2-tissue-compartment models with an additional blood volume parameter to the time–activity curves. <strong>Results:</strong> An irreversible single-tissue-compartment model was preferred in bone and skeletal muscle, a reversible 2-tissue-compartment model was preferred in kidney and lung, and a reversible single-tissue-compartment model was preferred in the other organs. Our results showed various levels of [¹⁸F]DPA-714 uptake in the 10 extracerebral organs. The highest mean volume of distribution was found in myocardium (33.27 ± 11.91 mL⋅cm⁻³), and the lowest mean volume of distribution was found in lung (5.12 ± 2.85 mL⋅cm⁻³). The mean influx rate was higher in bone than in skeletal muscle (respectively, 0.101 vs. 0.052 mL⋅cm⁻³⋅min⁻¹; <em>P</em> &lt; 0.001). <strong>Conclusion:</strong> The TSPO receptor is widely distributed over the entire body, with very high [¹⁸F]DPA-714 uptake in several organs. An irreversible model in bone and skeletal muscle and a reversible model in the other organs were preferred to describe [¹⁸F]DPA-714 kinetics. Further studies using [¹⁸F]DPA-714 to assess extracerebral inflammation should consider these kinetic differences among TSPO-rich organs.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"134 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis–Associated Interstitial Lung Disease","authors":"David M.L. Lilburn, Helen S. Garthwaite, Balaji Ganeshan, Thida Win, Nicholas J. Screaton, Luke R. Hoy, Darren Walls, Raymond Endozo, Robert I. Shortman, Francesco Fraioli, Athol U. Wells, Christopher P. Denton, Ashley M. Groves, Joanna C. Porter","doi":"10.2967/jnumed.125.269497","DOIUrl":"https://doi.org/10.2967/jnumed.125.269497","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.269497absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer","authors":"Shannon E. Lynch, Corinne Crawford, Addison L. Hunt, Luke L. Sligh, Yujun Zhang, Lyse A. Norian, Benjamin M. Larimer, Suzanne E. Lapi, Anna G. Sorace","doi":"10.2967/jnumed.124.268938","DOIUrl":"https://doi.org/10.2967/jnumed.124.268938","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268938absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}